Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-28
2010-12-14
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S358000
Reexamination Certificate
active
07851474
ABSTRACT:
Dipiperazinyl ketones and related analogues are provided, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).
REFERENCES:
patent: 4371517 (1983-02-01), Vanlergerhe et al.
patent: 4610984 (1986-09-01), Schonafinger et al.
patent: 5700801 (1997-12-01), Pieper et al.
patent: 5753659 (1998-05-01), Mills et al.
patent: 5965559 (1999-10-01), Faull et al.
patent: 6087357 (2000-07-01), Matsuo et al.
patent: 6090813 (2000-07-01), Waterson et al.
patent: 6225309 (2001-05-01), Faull et al.
patent: 6559140 (2003-05-01), Bennani et al.
patent: 6730672 (2004-05-01), Faull et al.
patent: 6951871 (2005-10-01), Aslanian et al.
patent: 6969718 (2005-11-01), Guzi et al.
patent: 7056942 (2006-06-01), Hildesheim et al.
patent: 7067507 (2006-06-01), Pulley et al.
patent: 2004/0019039 (2004-01-01), Dorwald et al.
patent: 2004/0034019 (2004-02-01), Tomlinson et al.
patent: 2004/0048843 (2004-03-01), Ting et al.
patent: 2004/0097483 (2004-05-01), Zeng et al.
patent: 2005/0107434 (2005-05-01), Sorensen et al.
patent: 2387613 (2001-05-01), None
patent: 1342649 (2002-04-01), None
patent: WO 96/20173 (1996-07-01), None
patent: WO 03/004480 (2003-01-01), None
patent: WO 03/097623 (2003-11-01), None
patent: WO 2004/101546 (2004-11-01), None
patent: WO 2005/014571 (2005-02-01), None
patent: WO 2006/014135 (2006-02-01), None
patent: WO 2006/014136 (2006-02-01), None
Vippagunta et al. Advanced Drug Delivery Reviews, 2001, 48, 3-26.
Tiligada et al. Expert Opinion on Investigational Drugs, 2009, 18(10), 1519-31.
Chavez et al. Brain Research, 2005, 1064, 1-9.
Esbenshade. Molecular Interventions, 2006, 6(2), 77-88.
Witjmans et al. Expert Opinion on Investigational Drugs, 2007, 16(7), 967-85.
Hancock et al. Expert Opinion on Investigational Drugs, 2006, 71, 1103-13.
“Type 1 Diabetes prevention”, http://diabetes.webmd.com/tc/type-1-diabetes-prevention, accessed May 26, 2009.
“Schizophrenia- Prevention”, http://www.webmd.com/schizophrenia/tc/schizophrenia-prevention, accessed Dec. 12, 2008.
Agrawal et al., (1984) Indian Journal of Chemistry 23B(7):650-654.
SciFinder, Registry No. 841246-56-8, (Jan. 18, 2005).
International Search Report and Written Opinion; International Application No. PCT/US06/29761; International Filing Date Jul. 28, 2006; Applicant's file reference N05.6203 (NEU-0041US); Date of Mailing Apr. 29, 2008; 12 pages.
Meclizine Hydrochloride Prescribing Information, revised Feb. 2004.
Caldwell Timothy M.
Gao Yang
Ge Ping
Han Bingsong
Ochterski Joseph W.
Cantor & Colburn LLP
Jarrell Noble
Neurogen Corporation
Wilson James O
LandOfFree
Dipiperazinyl ketones and related analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dipiperazinyl ketones and related analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dipiperazinyl ketones and related analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213329